Tesamorelin: Uses, Mechanism, and Side Effects

Many people living with HIV develop excess abdominal fat linked to lipodystrophy, a condition tied to body composition changes rather than overall weight gain. Tesamorelin is a lab-made peptide developed specifically to address this visceral fat accumulation.

Key takeaways

• Tesamorelin is approved under the brand name EGRIFTA SV for excess abdominal fat in HIV-infected adults with lipodystrophy.
• It works by stimulating the body's own growth hormone release rather than supplying growth hormone directly.
• It is weight neutral and is not indicated for general weight loss.
• Long-term cardiovascular safety has not been established, so ongoing benefit should be weighed against continued use.
• The most frequently reported issues in adverse event reports involve dosing and administration, not a specific organ system.

What Tesamorelin Is

Tesamorelin is a growth hormone-releasing factor (GHRF) analog, also called a GHRH analog. In laboratory studies it binds to the same pituitary receptors as the body's natural GHRF and stimulates it with similar potency. This prompts the pituitary gland to release endogenous growth hormone, which has both fat-metabolizing and tissue-building effects.

What Tesamorelin Is Approved For

Tesamorelin, sold as EGRIFTA SV, is approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label specifies it is weight neutral and is not intended for weight loss management. It also notes there is no evidence it improves compliance with antiretroviral therapy. The label recommends that clinicians reconsider continued treatment if a patient shows no reduction in visceral fat, since long-term cardiovascular safety has not been established. No boxed warning is present on the label.

What the Evidence Shows

Tesamorelin has been studied across 24 registered clinical trials. A phase 2 safety study evaluated the compound (referred to as TH9507) in people with stable type 2 diabetes and was completed. A separate phase 2 trial testing tesamorelin in COPD patients with muscle wasting was terminated before completion.

Reported Side Effects

Adverse event reports for tesamorelin most commonly involve issues with how the product is dosed or prepared, including product dose omission (285 reports), incorrect dose administered (164), and product preparation issues (121). Injection site reactions are also frequently reported, such as pain (141 reports) and bruising (89). Other reported terms include drug ineffectiveness (128), weight increase (97), and joint pain (95). These figures reflect the number of reports submitted, not confirmed rates of occurrence or proof that tesamorelin caused the event.